natgillin/translations-raw huggingface dataset:
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
Vložke morate pogosto pregledovati in jih ne smete uporabiti, če so navzoči strdki snovi ali se trdni beli delci držijo dna ali stene vložka, kar daje videz zamrznjenosti.
The cases were typical of secondary MDS/cancer therapy-related AML.
Praviloma je šlo za primere sekundarnega MDS/z zdravljenjem raka povezane AML.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis and calicivirosis, and every three years for panleucopenia.
Mačko je treba ponovno cepiti za vse sestavine cepiva eno leto po prvem cepljenju in nato vsako leto proti herpesvirusu rinotraheitisa in kalicivirusu ter vsake tri leta proti virusu panlevkopenije.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis and chlamydiosis, and every three years for panleucopenia.
Mačko je treba ponovno cepiti za vse sestavine cepiva eno leto po prvem cepljenju, nato pa vsako leto proti rinotraheitisu, kalicivirozi in klamidiozi, proti panleukopeniji pa vsaka tri leta.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis and feline leukaemia, and every three years for panleucopenia.
Mačko je treba ponovno cepiti za vse sestavine cepiva eno leto po prvem cepljenju, nato pa vsako leto proti rinotraheitisu, kalicivirozi in mačji levkemiji, proti panleukopeniji pa vsaka tri leta.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis, chlamydiosis and feline leukaemia, and every three years for panleucopenia.
Mačko je treba ponovno cepiti za vse sestavine cepiva eno leto po prvem cepljenju, nato pa vsako leto proti rinotraheitisu, kalicivirozi, klamidiozi in mačji levkemiji, proti panleukopeniji pa vsaka tri leta.
The cat should be revaccinated for all components one year after the first vaccination course, then every year.
Mačko je treba ponovno cepiti za vse sestavine cepiva eno leto po prvem cepljenju in nato vsako leto.
The catheter is kept closed until the next infusion.
Do naslednje infuzije mora biti kateter zaprt.
The cattle may also show some signs of slight pain at the site of injection for one day.
Pojavijo se lahko tudi znaki blažje bolečine na mestu injiciranja, ki pa ne trajajo več kot en dan.
The causal relationship of Ilaris to these events cannot be excluded.
Vzročne povezave med temi dogodki in zdravilom Ilaris ne moremo izključiti.
The causal relationship to the vaccine has not been established.
Vzročne zveze s cepivom niso ugotovili.
The cause of Alzheimer’s disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain.
Vzrok za Alzheimerjevo bolezen ni znan, vendar se domneva, da izguba spomina pri bolezni nastane zaradi motenj v prenosu signalov v možganih.
The CCR5-tropic HIV uses this protein to enter the cells.
CCR5-tropni HIV vstopi v celice prek te beljakovine.
The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B cell tumours.
Molekula CD20 je transmembranski fosfoprotein, izražen na limfocitih B od faze pred-B do faze zrelega limfocita B ter na tumorjih celic
The CD4% or plasma HIV RNA was not affected by vaccination.
Cepljenje ni vplivalo na odstotek CD4 ali vrednost HIV RNA v plazmi.
The ceftolozane in Zerbaxa is a type of antibiotic called a cephalosporin, which belongs to the wider group called ‘beta-lactams’.
Ceftolozan v zdravilu Zerbaxa je vrsta antibiotika, imenovanega cefalosporin, ki spada v večjo skupino, imenovano „betalaktamski antibiotiki“.
The cells are of human origin and genetically modified with a replication- defective γ-retroviral vector coding for the HSV-TK and ΔLNGFR genes so that these sequences are integrated in the genome of the host cells.
Celice so humanega izvora in so gensko spremenjene z replikacijsko okvarjenim γ- retrovirusnim vektorjem, ki kodira gene HSV-TK in ΔLNGFR, tako da se ta zaporedja vgradijo v genom gostiteljskih celic.
The cells are used to fill in the space where the cartilage has been damaged, thereby regenerating the damaged areas and helping to resolve the patient’s symptoms such as pain and problems moving the knee.
Celice so namenjene zapolnjevanju prostora, kjer je hrustanec poškodovan, s čimer se obnovijo poškodovana mesta in olajšajo bolnikovi simptomi, kot so bolečina in težave pri premikanju kolena.
the cells cannot be grown in the laboratory the increased cells do not meet all the quality requirements.
razmnožene celice ne izpolnjujejo zahtevanih kriterijev kakovosti.
The cells in giant cell tumour of bone are also activated via RANKL, and treatment with denosumab prevents them from growing and breaking down bone, allowing normal bone to replace the tumour.
Antigen RANKL aktivira tudi celice gigantocelularnega kostnega tumorja, zdravljenje z denosumabom pa preprečuje njihovo rast in razgradnjo kosti, s čimer normalnim kostnim celicam omogoča, da nadomestijo tumorske.
The cellular composition and the cell number per dose of Provenge will vary according to the patient’s leukapheresis.
Celična sestava in število celic na odmerek zdravila Provenge se razlikujeta glede na levkaferezo bolnika.
The cellular sequela of inhibition of topoisomerase-I by topotecan is the induction of protein- associated DNA single-strand breaks.
Celična posledica zaviranja topoizomeraze I je razpad posameznih verig DNA, na katere se veže encim, na dele.
The cellular sequela of inhibition of topoisomerase-I by topotecan is the induction of protein-associated DNA single-strand breaks.
Celična posledica zavrtja topoizomeraze I s topotekanom je nastanek prekinitev na enojni verigi DNA, vezani na beljakovino.
The central and peripheral volumes of distribution estimates for a patient with body weight of 70 kg (and 95% CI) were 5.66 (2.76, 11.6) L and 44.8 (33.2, 60.5) L, respectively.
Za bolnika s telesno maso 70 kg (in 95-odstotnim IZ) je bila ocena centralnega volumna porazdelitve 5,66 (2,76; 11,6) l in perifernega volumna porazdelitve 44,8 (33,2; 60,5) l.
The central tendency analysis indicated that all upper limits of the 90% CI for the LS mean change from Baseline in QTcF at all Cycle 2 Day 1 time points were <20 msec.
Analiza centralne tendence je pokazala, da so bile vse zgornje meje 90-odstotnega intervala zaupanja spremembe povprečja najmanjših kvadratov vrednosti QTcF glede na izhodišče < 20 ms v vseh časovnih točkah 1. dne 2. cikla.
the centre of your vision gets blurry or has shadows;
postane centralni del vidnega polja zamegljen ali se vam pred očmi pojavljajo sence;
The Certificate of Analysis is marked as rejected.
je analizni certifikat označen kot zavrnjen,
The Cetrotide powder in the vial and the sterile water (solvent) in the pre-filled syringe have the same expiry date.
Prašek Cetrotide v viali in sterilna voda (vehikel) v napolnjeni injekcijski brizgi imata enak datum izteka roka uporabnosti.
The CFA-72h was determined by a 72-hour stool collection during both treatments, when both fat excretion and fat ingestion were measured.
Koeficient CFA–72h so pri obeh zdravljenjih določili z odvzemanjem vzorcev blata v obdobju 72 ur ter z merjenjem izločenih in zaužitih maščob.
The chance of experiencing these side effects decreases with subsequent doses of Zoledronic acid Teva Generics.
Verjetnost, da pride do teh neželenih učinkov, se pri nadaljnjih odmerjanjih zdravila Zoledronska kislina Teva Generics zmanjšuje.
The chance of having a blood clot may be higher if you have any other conditions that increase this risk (See section 2 for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot.)
Verjetnost za nastanek krvnega strdka je lahko večja, če imate še kakšno drugo stanje, ki poveča tveganje (za več informacij o stanjih, ki povečajo tveganje za krvne strdke, in o simptomih krvnih strdkov glejte poglavje 2).
The chance of having a side effect is described by the following categories:
Verjetnost, da se bo pri vas pojavil neželeni učinek je opisana s sledečimi kategorijami:
The chances of the capsule breaking into pieces are increased if the capsule is pierced more than once during Step 6.
Možnost, da se bo kapsula razlomila na koščke, je večja, če jo v 6. koraku prebodete več kot enkrat.
The chances of the capsule shattering will be increased if the capsule is pierced more than once (step 7).
Možnost, da se kapsula tako zdrobi, je večja, če kapsulo nehote predrete več kot enkrat (7. korak).
The change from baseline in mean time-averaged QTcF interval at steady state was 6 msec.
V ravnovesnem stanju je prišlo do srednjega časovno povprečnega podaljšanja intervala QTcF za 6 milisekund glede na izhodišče.
The change in mean eGFR from baseline at Week 24 was -1.17 ml/min/1.73m2 in the saxagliptin plus dapagliflozin plus metformin group, -0.46 ml/min/1.73 m2 in saxagliptin plus metformin, and 0.81 ml/min/1.73m2 in dapagliflozin plus metformin.
Sprememba povprečnega eGFR od izhodišča do 24. tedna je bila -1,17 ml/min/1,73 m2 pri prejemnikih kombinacije saksagliptina, dapagliflozina in metformina, -0,46 ml/min/1,73 m2 pri prejemnikih kombinacije saksagliptina in metformina ter 0,81 ml/min/1,73 m2 pri prejemnikih kombinacije dapagliflozina in metformina.
The change in pain severity was measured by the patients ranking their pain on a scale from 0 to 10.
Spremembo v jakosti bolečine so ocenili bolniki, ki so bolečino ovrednotili na lestvici od 0 do 10.
The change in pulmonary function and the need for pulmonary function monitoring
premembah delovanja pljuč in potrebi po nadziranju pljučnega delovanja,
The change may be more noticeable if you are only treating one eye.
Omenjene spremembe lahko ostanejo trajne in so opaznejše, če zdravite le eno oko.
The change may be more noticeable if you are only treating one eye.
Če vam zdravijo le eno oko, so spremembe lahko bolj opazne.
The change means that it is absorbed faster by the body than human insulin, and therefore starts to work sooner.
Razlika je v tem, da mogoča hitrejšo absorpcijo v telesu, zaradi česar lahko učinkuje hitreje kot humani insulin.
The changes in ombitasvir, paritaprevir, and ritonavir exposures in subjects with mild, moderate and severe renal impairment are not considered to be clinically significant.
Spremembe izpostavljenosti ombitasvirju, paritaprevirju in ritonavirju pri osebah z blago, zmerno in hudo okvaro ledvic ne veljajo za klinično pomembne.
The changes in PANSS total scores from baseline to Week 8 and Week 26 were numerically similar between the INVEGA and aripiprazole treatment groups.
Spremembe v vrednosti PANSS od izhodišča do 8. in 26. tedna so bile pri skupini, zdravljeni z zdravilom INVEGA in skupini z aripiprazolom številčno podobne.
The changes in the kidney in rats (glomerulonephritis, renal tubular obstruction, crystalline material in renal tubule) and in the liver of mice and rats (hepatocellular hypertrophy, hepatocyte necrosis, bile duct hyperplasia, crystalline material in bile ducts) were seen at exposures more than 10-fold (mice) and 2-fold (rats) the human exposure at the maximum recommended therapeutic dose of 20 mg/day.
Spremembe v ledvicah podgan (glomerulonefritis, obstrukcija ledvičnih tubulov, kristalinična snov v ledvičnih tubulih) in v jetrih miši in podgan (hipertrofija jetrnih celic, nekroza hepatocitov, hiperplazija žolčevoda, kristalinična snov v žolčevodih) so opazili pri izpostavljenostih, večjih od 10-kratne (miši) in 2- kratne (podgane) izpostavljenosti za človeka pri največjem priporočenem terapevtskem odmerku 20 mg/dan.
The changes in the reproductive organs and androgen-sensitive organs are consistent with the pharmacology of abiraterone.
Spremembe reproduktivnih in na androgene občutljivih organov so v skladu s farmakologijo abiraterona.
The changes observed at the low dose of the 13-week studies can be classified as minimal and fully reversible.
Spremembe, ki so jih zasledili po dajanju majhnih odmerkov v 13- tedenskih raziskavah, lahko opredelimo kot minimalne in popolnoma reverzibilne.
The characteristics
O značilnostih in
The characterization of the safety profile of Menveo in adolescents and adults is based on data from five randomised controlled clinical trials including 6401 participants (from 11-65 years of age) who received Menveo.
Opredelitev varnostnega profila cepiva Menveo pri mladostnikih in odraslih temelji na podatkih petih randomiziranih kontroliranih kliničnih preskušanjih s 6.401 udeleženci (starimi od 11 do 65 let), ki so prejeli cepivo Menveo.
The characterization of the safety profile of Menveo in children 2 to 10 years of age is based on data from four clinical trials in which 3181 subjects received Menveo.
Opredelitev varnostnega profila cepiva Menveo pri otrocih, starih 2 do 10 let, temelji na podatkih štirih kliničnih študij, v katerih je bilo s cepivom Menveo cepljenih 3.181 oseb.
The chart below will help you find out whether you are overweight and whether alli is right for you.
Spodnja tabela vam bo pomagala ugotoviti, ali imate čezmerno telesno maso in ali je zdravilo alli pravo za vas.
The checklist also includes information on the tests and monitoring that should be carried out in patients before and after starting or when restarting treatment with Gilenya.
Na seznamu bodo navedene tudi informacije o testiranju in opazovanju bolnikov, ki ju je treba izvajati pred začetkom zdravljenja z zdravilom Gilenya in po njem.
The checklist should include tick-boxes to check and document:
Obrazec mora vključevati okvirčke za preverjanje in mora dokumentirati:
The chemical and physical in-use stability has been demonstrated for up to 24 hours at 2 - 8°C, followed by up to 12 hours at not more than 25oC.
Kemična in fizikalna stabilnost med uporabo sta dokazani do 24 ur pri temperaturi od 2 do 8 °C in nato do 12 ur pri največ 25 °C.
The chemical and physical in-use stability has been demonstrated for up to 24 hours at 2-8°C. Once removed from refrigeration to room temperature, the diluted product must be used within 6 hours.
Kemična in fizikalna stabilnost med uporabo sta dokazani do 24 ur pri temperaturi od 2 - 8 °C. Ko je redčeno zdravilo enkrat vzeto iz hladilnika in dano na sobno temperaturo, ga je treba uporabiti v 6 urah.
The chemical and physical in-use stability of the reconstituted solution at a concentration of 1 mg/ml has been demonstrated for 3 days at 20°C-25°C stored in the original vial and/or a syringe.
Rekonstituirana raztopina s koncentracijo 1 mg/ml je kemično in fizikalno stabilna 3 dni pri temperaturi 20−25 C, če jo pred uporabo shranjujemo v originalni viali in/ali injekcijski brizgi.
The chemical and physical in-use stability of the reconstituted solution of 2.5 mg/ml has been demonstrated for 8 hours at 20°C-25°C stored in the original vial and/or a syringe.
Rekonstituirana raztopina s koncentracijo 2,5 mg/ml je kemično in fizikalno stabilna 8 ur pri temperaturi 20−25 C, če jo pred uporabo shranjujemo v originalni viali in/ali injekcijski brizgi.
The chemical and physical in-use stability of the undiluted or diluted concentrate (between 1 and 4 mg/ml) has been demonstrated for 24 hrs at 25°C and 2°C to 8°C. If not used immediately, the infusion solution (undiluted or diluted) may be stored for up to 24 hours in a refrigerator (2°C to 8°C) or at room temperature (20°C to 25°C).
Dokazano je bilo, da je nerazredčen ali razredčen koncentrat (med 1 in 4 mg/ml) kemijsko in fizikalno stabilen 24 ur, če se ga shranjuje pri temperaturi do 25 °C ali pri temperaturi med 2 °C in 8 °C. Raztopino za infundiranje (nerazredčeno ali razredčeno), ki ne bo uporabljena takoj, se lahko do 24 ur shranjuje v hladilniku (2 °C do 8 °C) ali pri sobni temperaturi (20 °C do 25 °C).
The chemical and physical stability of the diluted solution has been demonstrated for 8 hours at 25°C.
Raztopina ostane kemično in fizično stabilna osem ur, če jo hranimo pri temperaturi do 25 °C.
The chemical and physical stability of Vistide admixed with saline has been demonstrated in glass bottles, in infusion bags composed of either polyvinyl chloride (PVC) or ethylene/propylene copolymer, and in PVC based vented IV administration sets.
Kemična in fizikalna stabilnost zdravila Vistide, zmešanega s fiziološko raztopino, je dokazana v steklenicah, infuzijskih vrečkah iz polivinilklorida (PVC) ali etilen/propilenskega kopolimera ter v ventiliranih kompletih za intravensko (i.v.) apliciranje, izdelanih na podlagi PVC.
The chemical structure of eslicarbazepine acetate is similar to that of carbamazepine, and it is possible that patients who are positive for HLA-B*1502 may also be at risk for SJS after treatment with Eslicarbazepine acetate.
Kemična struktura eslikarbazepinacetata je podobna kot pri karbamazepinu, zato je možno, da obstaja pri bolnikih, pozitivnih na HLA-B*1502, tveganje za SJS tudi po zdravljenju z eslikarbazepinacetatom.
The chemotherapy should be given after MabThera administration.
Kemoterapijo dajemo po infuziji zdravila MabThera.
The chemotherapy should be given after the MabThera administration.
Kemoterapijo boste dobili po infuziji zdravila MabThera.
The chewable tablets are for bigger children weighing at least 11 kg, while the 400-mg tablets are for adults and children from six years of age weighing more than 25 kg.
Žvečljive tablete so namenjene starejšim otrokom, ki tehtajo najmanj 11 kilogramov, medtem ko so 400-miligramske tablete namenjene odraslim in otrokom, starejšim od šest let, ki tehtajo najmanj 25 kilogramov.
The chewable tablets are white to off-white, faceted and triangular in shape, debossed with ‘alli’.
Žvečljiva tableta je bele do belkaste barve, brušena, trikotne oblike, debeline 12 mm, vtisnjen je napis
The child must avoid heavy exercise especially when the weather is hot
e mora izogibati pretirani telesni vadbi,
The child must avoid heavy exercise especially when the weather is hot
e mora izogibati pretirani telesni vadbi, zlasti ob vročem vremenu;
The child must drink plenty of cold water
mora piti veliko mrzle vode;
The child must not take any of these medicines: carbonic anhydrase inhibitors (like topiramate and acetazolamide), and anticholinergic agents (like clomipramine, hydroxyzine, diphenhydramine, haloperidol, imipramine and oxybutynin).
ne sme jemati nobenega od naslednjih zdravil: zaviralcev karboanhidraze (kot sta topiramat in acetazolamid) in antiholinergičnih zdravil (kot so klomipramin, hidroksizin, difenhidramin, haloperidol, imipramin in oksibutinin).
The child must swallow the tablets with a drink such as water or milk.
Otrok mora tablete pogoltniti s pijačo, kot je voda ali mleko.
The child must take PREZISTA always together with ritonavir.
Otrok mora zdravilo PREZISTA vedno zaužiti skupaj z ritonavirjem.
The child must take PREZISTA with food.
Otrok mora zdravilo PREZISTA zaužiti s hrano.
The child must take the appropriate doses of PREZISTA and ritonavir two times per day or once a day.
Predpisani odmerek zdravil PREZISTA in ritonavirja mora otrok zaužiti dvakrat na dan ali enkrat na dan.
The child should not use Enbrel with medicines that contain the active substance anakinra or abatacept.
Zdravila Enbrel vi ali otrok ne smete jemati skupaj z zdravili, ki vsebujejo zdravilno učinkovino anakinro ali abatacept.
The child should stay cool especially in hot weather
mora ostati hladen, zlasti ob vročem vremenu;
The Child-Pugh classification divides patients into groups A, B, and C, or "Mild", "Moderate" and "Severe" corresponding to scores of 5-6, 7-9 and 10-15, respectively.
V skladu s Child-Pughovo klasifikacijo stopenj jetrne okvare bolnike razdelimo v skupine na blage, srednje ali hude oziroma glede na število točk na stopnjo A (5 do 6 točk), B (7 do 9 točk) ali C (10 do 15 točk).
The child-resistant screw cap should be removed by pushing it down firmly and turning it anti- clockwise (Figure B).
Za otroke varno navojno zaporko je treba odstraniti tako, da se jo močno pritisne navzdol in obrne v nasprotni smeri urnega kazalca (slika B).
The children in this study were given either Synflorix or a comparator vaccine which was not active against S. pneumoniae and were followed up for an average of 30 months.
Otroci so v tej študiji prejemali cepivo Synflorix ali primerjalno cepivo, ki ni učinkovalo proti okužbi z bakterijo S. pneumoniae, spremljali pa so jih povprečno 30 mesecev.
The children received one dose of Synflorix in the first study and two doses in the second study.
Otroci so v prvi študiji prejeli en odmerek cepiva Synflorix, v drugi študiji pa dva odmerka.
The children were followed up for an average of around two years to see how effective Synflorix was in preventing invasive disease.
Otroke so v povprečju spremljali približno dve leti, da bi ugotovili, kako učinkovito je bilo cepivo Synflorix pri preprečevanju invazivne bolezni.
The children were followed up until the end of their second year of life.
Otroke so spremljali do konca njihovega drugega leta starosti.
The child’s breathing slows down or stops e.g. slow or shallow breathing or blue lips
e otrokovo dihanje upočasni ali zaustavi; n.pr., če je dihanje počasno ali plitvo ali ustnice pomodrijo;
The child’s breathing slows down or stops e.g. slow or shallow breathing or blue lips You observe signs of a heart attack which may include chest pain or pain that spreads to the neck and shoulders and down the left arm
opazite znake srčnega infarkta, med katere lahko sodijo bolečine v prsih ali bolečina, ki se širi v vrat in rame in po levici navzdol;
The child’s doctor may decide to stop treatment with Sialanar if side effects cannot be managed by reducing the dose.
Otrokov zdravnik lahko sprejme odločitev, da bo prenehal zdravljenje z zdravilom Sialanar, če neželenih učinkov ni mogoče obvladovati z zmanjšanjem odmerka.
The chimeric replicons carrying NS5A genes from genotype 2b, 5a, 6a and 6e were used for testing ledipasvir while the chimeric replicons carrying NS5B genes from genotype 2b, 5a or 6a were used for testing sofosbuvir.
Himerični replikoni, ki nosijo gene NS5A genotipov 2b, 5a, 6a in 6e, so bili uporabljeni za preskušanje ledipasvirja, himerični replikoni, ki nosijo gene NS5B genotipov 2b, 5a ali 6a so bili uporabljeni za preskušanje sofosbuvirja.
The CHMP agrees with the scientific conclusions made by the PRAC and recommended changes to the SmPC and package leaflet accordingly.
Odbor za zdravila za uporabo v humani medicini (CHMP) se strinja z znanstvenimi zaključki odbora PRAC in priporoča ustrezne spremembe v SmPC in navodilu za uporabo.
The CHMP agrees with the scientific conclusions made by the PRAC.
CHMP se strinja z znanstvenimi izsledki, ki jih je pridobil PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
CHMP se strinja z znanstvenimi zaključki, ki jih je predlagal PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
CHMP se strinja z znanstvenimi zaključki, ki jih je sprejel PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP se strinja z znanstevimi zaključki odbora PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP se strinja z znanstvenim zaključkom, ki ga je pripravil PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP se strinja z znanstvenimi zaključki PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP soglaša s znanstvenimi zaključki odbora PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP soglaša z znanstvenimi zaključki PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP soglaša z znanstvenimi zaključki, ki jih je podal odbor PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor za zdravila za uporabo v humani medicini (CHMP) se strinja z znanstvenimi sklepi, ki jih je sprejel odbor PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor za zdravila za uporabo v humani medicini (CHMP) se strinja z znanstvenimi zaključki odbora PRAC.